Trial Profile
Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Arthritis; Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms ABC
- 15 Nov 2023 Results assessing molecular predictors of treatment response in two trials of abatacept in systemic lupus erythematosus (ABC Study and ACCESS), presented at the ACR Convergence 2023.
- 19 Jan 2022 Status changed from active, no longer recruiting to completed.
- 15 Nov 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.